Assessing the Potential Cost Effectiveness of Pneumococcal Vaccines in the US

Drugs & Aging ◽  
1999 ◽  
Vol 15 (Supplement 1) ◽  
pp. 31-36 ◽  
Author(s):  
John Hutton ◽  
Cynthia Iglesias ◽  
Tom O. Jefferson
Vaccine ◽  
2011 ◽  
Vol 29 (45) ◽  
pp. 8077-8085 ◽  
Author(s):  
Anthony T. Newall ◽  
Prudence Creighton ◽  
David J. Philp ◽  
James G. Wood ◽  
C. Raina MacIntyre

2019 ◽  
Vol 10 (9) ◽  
pp. 555-561
Author(s):  
Louise Rosenmayr-Templeton

This industry update features a round-up of pharmaceutical news in May 2019 based on press releases and websites. The month was characterized by the achievement of significant milestones in gene therapy. The biggest of these was the US FDA’s approval of Zolgensma®. This medicine sums up the promise and price of genetic medicine. On one hand the clinical results show Zolgensma can dramatically improve the prognosis for infants with spinal muscular atrophy after just one administration, while on the other, it has been priced at around US$2.1 million. With more such therapies likely to reach the market, the debate on Zolgensma goes beyond cost, to overall affordability, the true meaning of cost–effectiveness and how to reward companies for effective, innovative medicines.


2021 ◽  
pp. 089198872098890
Author(s):  
Angeliki Bogosian ◽  
Catherine S. Hurt ◽  
John V. Hindle ◽  
Lance M. McCracken ◽  
Debora A. Vasconcelos e Sa ◽  
...  

Mindfulness-based group therapy is a rapidly growing psychological approach that can potentially help people adjust to chronic illness and manage unpleasant symptoms. Emerging evidence suggests that mindfulness-based interventions may benefit people with Parkinson’s. The objective of the paper is to examine the appropriateness, feasibility, and potential cost-effectiveness of an online mindfulness intervention, designed to reduce anxiety and depression for people with Parkinson’s. We conducted a feasibility randomized control trial and qualitative interviews. Anxiety, depression, pain, insomnia, fatigue, impact on daily activities and health-related quality of life were measured at baseline, 4, 8, and 20 weeks. Semi-structured interviews were conducted at the end of the intervention. Participants were randomized to the Skype delivered mindfulness group (n = 30) or wait-list (n = 30). Participants in the mindfulness group were also given a mindfulness manual and a CD with mindfulness meditations. The intervention did not show any significant effects in the primary or secondary outcome measures. However, there was a significant increase in the quality of life measure. The incremental cost-effectiveness ratio was estimated to be £27,107 per Quality-Adjusted Life Year gained. Also, the qualitative study showed that mindfulness is a suitable and acceptable intervention. It appears feasible to run a trial delivering mindfulness through Skype, and people with Parkinson’s found the sessions acceptable and helpful.


2014 ◽  
Vol 32 (12) ◽  
pp. 2411-2421 ◽  
Author(s):  
Oliver Chung ◽  
Wanpen Vongpatanasin ◽  
Klaus Bonaventura ◽  
Yair Lotan ◽  
Christian Sohns ◽  
...  

2011 ◽  
Vol 14 (7) ◽  
pp. A276-A277
Author(s):  
M.A. Lutz ◽  
K. Luciani ◽  
G. Morales ◽  
D.R. Strutton ◽  
C.S. Roberts ◽  
...  

2015 ◽  
Vol 18 (7) ◽  
pp. A457-A458 ◽  
Author(s):  
C Graham ◽  
H Knox ◽  
LM Hess ◽  
M Jen ◽  
G Cuyun Carter ◽  
...  

2013 ◽  
Vol 47 (5) ◽  
pp. 671-685 ◽  
Author(s):  
Birgitta von Schéele ◽  
Maria Fernandez ◽  
Susan Lynn Hogue ◽  
Winghan Jacqueline Kwong

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Eric Jutkowitz ◽  
Laura N. Gitlin ◽  
Laura T. Pizzi ◽  
Edward Lee ◽  
Marie P. Dennis

Evaluating cost effectiveness of interventions for aging in place is essential for adoption in service settings. We present the cost effectiveness of Advancing Better Living for Elders (ABLE), previously shown in a randomized trial to reduce functional difficulties and mortality in 319 community-dwelling elders. ABLE involved occupational and physical therapy sessions and home modifications to address client-identified functional difficulties, performance goals, and home safety. Incremental cost-effectiveness ratio (ICER), expressed as additional cost to bring about one additional year of life, was calculated. Two models were then developed to account for potential cost differences in implementing ABLE. Probabilistic sensitivity analyses were conducted to account for variations in model parameters. By two years, there were 30 deaths (9: ABLE; 21: control). Additional costs for 1 additional year of life was $13,179 for Model 1 and $14,800 for Model 2. Investment in ABLE may be worthwhile depending on society's willingness to pay.


2017 ◽  
Vol 35 (5) ◽  
pp. 575-589 ◽  
Author(s):  
Asrul Akmal Shafie ◽  
Hui Yee Yeo ◽  
Laurent Coudeville ◽  
Lucas Steinberg ◽  
Balvinder Singh Gill ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document